NKGen Biotech, Inc.: debt financing — NKGen Biotech gets $412.5K additional convertible loan at $0.08/share; increases consideration shares to 12.15M

NKGen Biotech, Inc.

Additional loan of $412,500 (net $375,000) from AlpineBrook Capital; convertible at $0.08/share and warrant exercisable at $0.08/share.
Consideration shares increased to 12,147,280, to be delivered in five installments over 25 months.
Voting agreement with major shareholders to support increase in authorized shares for conversion and warrant exercise.
Loan matures on Maturity Date under existing Loan Agreement; interest at Applicable Rate, 360-day year.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

NKGen Biotech, Inc. incurred convertible notes of $412,500 with AlpineBrook Capital GP I Limited at at the Applicable Rate (as defined in the Loan Agreement).

Instrument: convertible notes
Principal: $412,500
Counterparty: AlpineBrook Capital GP I Limited
Rate: at the Applicable Rate (as defined in the Loan Agreement)
Event: incurrence

Exact text from the filing

Pursuant to the Second Amendment, the Lender agreed to extend an additional loan to the Borrowers in the principal amount of $412,500 (the “ Additional Loan #2 ”)

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.7

NKGen Biotech, Inc. entered into Voting Agreement with AlpineBrook Capital GP I Limited, Graf Acquisition Partners IV LLC, NKGen Biotech Korea Co., Ltd., and Paul Song (effective 2026-05-15).

Action: entry
Counterparty: AlpineBrook Capital GP I Limited, Graf Acquisition Partners IV LLC, NKGen Biotech Korea Co., Ltd., and Paul Song
Effective: 2026-05-15

Exact text from the filing

the Company, the Lender, Graf Acquisition Partners IV LLC, NKGen Biotech Korea Co., Ltd., and Paul Song entered into a Voting Agreement, dated May 15, 2026 (the “ Voting Agreement ”)

View on SEC.gov

Browse all debt financings →

Source: SEC EDGAR

accession 0001213900-26-060160

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.